The myeloma bone marrow microenvironment promotes proliferation of malignant plasma cells 29 and resistance to therapy. Interleukin-6 (IL-6) and downstream JAK/STAT signaling are thought 30 to be central components of these microenvironment-induced phenotypes. In a prior drug 31 repurposing screen, we identified tofacitinib, a pan-JAK inhibitor FDA-approved for rheumatoid 32 arthritis, as an agent that may reverse the tumor-stimulating effects of bone marrow 33 mesenchymal stromal cells. Here, we validated both in vitro, in stromal-responsive human 34 myeloma cell lines, and in vivo, in orthotopic disseminated murine xenograft models of 35 myeloma, that tofacitinib showed both single-agent and combination therapeutic efficacy in 36 myeloma models. Surprisingly, we found that ruxolitinib, an FDA-approved agent targeting 37 JAK1 and JAK2, did not lead to the same anti-myeloma effects. Combination with a novel 38 irreversible JAK3-selective inhibitor also did not enhance ruxolitinib effects. RNA-seq and 39 unbiased phosphoproteomics revealed that marrow stromal cells stimulate a JAK/STAT-40 mediated proliferative program in myeloma plasma cells, and tofacitinib reversed the large 41 majority of these pro-growth signals. Taken together, our results suggest that tofacitinib 42 specifically reverses the growth-promoting effects of the tumor microenvironment through 43 blocking an IL-6-mediated signaling axis. As tofacitinib is already FDA-approved, these results 44 can be rapidly translated into potential clinical benefits for myeloma patients. 45 46 47
Introduction 48
Multiple myeloma (MM) is the second-most common hematologic malignancy in the United 49
States and still has no known cure. A major therapeutic challenge in MM is that patients 50 undergo numerous cycles of response to therapy followed by disease relapse after the 51 development of resistance. Years of research have revealed that a major driver of malignant 52 plasma cell proliferation, as well as therapeutic resistance, is signaling to the tumor cells from 53 the bone marrow microenvironment (reviewed in refs. 1-3). Cell types within the bone marrow 54 that influence myeloma plasma cells include mesenchymal stromal cells, osteoblasts, osteoclasts, 55 and multiple classes of immune cells 1-3 . Overcoming the growth-promoting phenotype of the 56 bone marrow microenvironment is thought to be a promising therapeutic strategy in MM. 57
One approach to identifying new therapeutic agents for many diseases is drug repurposing. 58
In this context, a large library of drugs, all of which are either FDA-approved or at the minimum 59 shown to be safe in humans, is screened against the biological system of interest 4,5 . The premise 60 behind these screens is that small molecules initially designed for one indication may actually 61 have beneficial effects across other diseases. In fact the use of thalidomide in multiple myeloma 62 is one of the most impactful examples of successful drug repurposing. If new indications are 63 found for already existing drugs, clinical development times and associated costs can be 64 drastically reduced, accelerating potential benefits to patients 6, 7 . 65
To identify agents which may reverse the tumor-promoting effects of the MM bone marrow 66 microenvironment, we recently reported a repurposing screen of 2,684 compounds, against three 67 MM cell lines, either grown alone (monoculture) or in co-culture with MM patient-derived bone 68 marrow mesenchymal stromal cells 8 . From that screen, we identified tofacitinib citrate, an FDA-69 approved small molecule for the treatment of rheumatoid arthritis (RA), sold under the trade 70 name Xeljanz, as an agent which may reverse stromal-induced growth proliferation of malignant 71 plasma cells. 72
Tofacitinib citrate is a potent inhibitor of all four members of the Janus kinase (JAK) family, 73 with preferential inhibition of JAK1 and JAK3 over JAK2 and TYK2 in cellular assays 9 . JAK 74 signaling, mediated by the downstream STAT transcription factors, is necessary for lymphocyte 75 stimulation in response to encountered antigens 10 . Therefore, JAK inhibition holds promise for 76 the treatment of autoimmune diseases like RA 11 . In parallel, the JAKs have gained interest as 77 therapeutic targets in MM as they mediate signaling via interleukin-6 (IL-6). IL-6 is secreted by 78 many cell types within the bone marrow microenvironment, as well as by malignant plasma cells 79 themselves, and it is thought that proliferation of malignant plasma cells within the human bone 80 marrow is dependent on this cytokine 12 . This dependence on IL-6 was underscored by the recent 81 development of a patient-derived xenograft model of MM, where primary plasma cell growth 82 only occurred in immunocompromised mouse bone marrow after knock-in of human IL-6 13 . 83
Therefore, abrogating IL-6 signaling via JAK inhibition is a promising therapeutic strategy in 84 MM 14 
RNA-seq 130
For co-culture RNA-seq, 5x10 6 MM.1S cells were grown in co-culture with 3x10 6 HS5 cells for 131 24 hr. All cells were harvested by Accutase incubation for 10 min at 37 C to separate MM.1S 132 from HS5 into a single-cell suspension. Cells were then separated using CD138+ MicroBeads 133 (Miltenyi) on a Miltenyi MidiMACS system. CD138+ enrichment to >95% was verified by flow 134 cytometry for mCherry expression ( Supplementary Fig. 1 ). MM.1S harvested from co-culture, 135 as well as MM.1S and HS5 grown in monoculture, were then processed for mRNA-seq as 136 previously described 23 . RNA-seq performed on HS5 stromal cells alone further allowed for 137 filtering of highly expressed stromal cell genes that could interfere with analysis of MM.1S cells 138 in co-culture even at <5% contamination. Significantly upregulated transcripts were identified 139 by DESeq 24 and bioinformatic analysis was performed using Enrichr 25 . Raw sequencing data are 140 available at the GEO repository (Accession number GSE99293). 
Tofacitinib targets the BM microenvironment and reverses bone marrow stromal cell-201 mediated growth promotion 202
To initially validate findings from our drug repurposing screen, we co-cultured the human MM 203 cell line MM.1S, which was included in the screen 8 , with the immortalized bone marrow stromal 204 cell lines HS5 and HS27A. We found that after 24h of co-culture, MM.1S cell numbers 205 approximately doubled compared to monoculture growth after 24h, confirming stromal-induced 206 proliferative signaling in this cell line, as seen in the screen. Tofacitinib treatment for 24 hr 207 reduced MM.1S cell numbers in a dose-dependent manner, such that at >1 µM tofacitinib, 208 MM.1S cell numbers in coculture return to approximately monoculture levels ( Fig. 1A) . 209
Tofacitinib has no effect on MM.1S cell viability alone nor on HS5 or HS27A alone ( Fig. 1B) . 210
We further studied the effect of tofacitinib on several other immortalized MM cell lines. In 211 monoculture we found that tofacitinib only demonstrates anti-MM activity in the IL-6 secreting 212 line U266 and in the IL-6 dependent cell line INA-6, with minimal to no effect on the other MM 213 cell lines (Fig. 1C ). We further evaluated four myeloma cell lines (U266, MM.1S, RPMI-8226, 214 JJN-3) in which luciferase was stably expressed, allowing for distinction of MM cell viability 215 versus stromal cell viability in co-culture, in the compartment-specific bioluminescence assay 21 . 216
After 24 hr of growth followed by 24 hr of drug exposure, only the stromal-responsive cell lines 217 MM.1S and U266 exhibit any sensitivity to tofacitinib treatment ( Fig. 1D ). Taken together, 218 these results suggest that tofacitinib selectively targets the growth-promoting interaction between 219 MM cells and the stromal microenvironment. These results further suggest that MM.1S is an 220 appropriate cell line candidate for further study, as it recapitulates the growth-promoting effects 221 of the bone marrow microenvironment known to occur in patients. 222 223 Tofacitinib inhibits IL-6 driven growth promotion in coculture with bone marrow stromal 224 cells 225
To further characterize the nature of pro-growth signaling between the stromal cell 226 microenvironment and MM plasma cells, we performed RNA-seq on MM.1S cells grown alone 227 or grown in co-culture with HS5 stromal cells. We first noticed that the most significantly 228 upregulated transcript in MM.1S in the co-culture setting was SOCS3, part of a well-229 characterized negative feedback mechanism strongly induced by JAK-STAT activation 10 ( Fig.  230 2A). We further examined all 67 transcripts significantly upregulated in MM.1S in the co-231 culture vs. monoculture setting (p < 0.005 per DESeq tool 24 ; listed in Supplementary Dataset 1). 232
Using the Enrichr tool 25 , ChEA analysis of ChIP-seq datasets 28 found the most significant 233 enrichment of STAT3-binding sites at the promoter of these upregulated transcripts, among all 234 transcription factors (Fig. 2B ). Furthermore, Panther 29 pathway analysis found the only two 235 significantly enriched pathways to be related to JAK/STAT signaling and interleukin signaling 236 ( Fig. 2C ). Taken together, these RNA-seq findings are most consistent with a mechanism where 237 IL-6 secreted from stromal cells mediates proliferation by activating JAK/STAT signaling, with 238 STAT3 playing a central role 30 . 239
We further investigated this mechanism by confirming that MM.1S cells stimulated with 240 50 ng/mL recombinant human IL-6 exhibited growth promotion similar to that induced by 241 coculture with stromal cells, suggesting that IL-6 is the primary cytokine mediating stromal-cell 242 induced proliferation (Fig. 2D ). Tofacitinib was capable of partially reversing this IL-6 induced 243 growth promotion in MM.1S at drug concentrations similar to those found for phenotypic effects 244 for stromal cell co-culture. We note that we did not find complete reversal of the growth 245 promotion, however, perhaps indicating that the high doses of recombinant IL-6 used here may 246 lead to residual proliferative signaling not fully blocked by tofacitinib. 247
We further took advantage of publicly available RNA-seq data across a large panel of 248 MM cell lines (http://www.keatslab.org/data-repository) to look for relationships between IL-6 249 and IL-6R expression and sensitivity to tofacitinib ( Fig. 3E-F) . Consistent with prior studies 31 , 250 only U266 expresses detectable levels of IL-6, whereas both U266 and MM.1S express relatively 251 high levels of IL-6R compared to other cell lines examined in Fig. 1, suggesting a relationship  252 between IL-6, IL-6R, and sensitivity to tofacitinib. 253 254
Tofacitinib inhibits JAK/STAT signaling 255
Given the proposed mechanism above, we chose to further evaluate downstream effects of IL-6-256 mediated stimulation and subsequent tofacitinib inhibition of the JAK/STAT pathway. Two of 257 the primary downstream mediators of IL-6R and JAK activation are thought to be pro-258 proliferation signaling by STAT3 and inhibitory signaling by STAT1 30 . As expected, we found 259 that STAT3 and STAT1 phosphorylation in MM.1S dramatically increases when in coculture 260 with HS5 ( Fig. 3A and 3B ). 1 µM tofacitinib inhibits STAT3 phosphorylation in MM.1S cells in 261 coculture almost to monoculture level by 2 hrs of treatment, suggestive of on-target effects. 262
Phosphorylation of JAK1, JAK2, and TYK2, which can also activate STAT3, were also studied. 263
We found evidence of a "rebound" effect by 24h of treatment, mediated by well-characterized 264 feedback mechanisms 10 , serving to phosphorylate the JAKs and subsequently re-activate STAT3. 265
Despite this rebound of STAT3 activation, however, MM growth continues to be inhibited based 266 on dose-response results of tofacitinib treatment at 24 hours. 267
As tofacitinib is known to potently inhibit JAK3, also of interest was an increase in JAK3 268 expression in MM.1S in coculture versus monoculture, found both by RNA-seq ( Fig. 2A) and 269
Western blot (Fig. 3C ). However, tofacitinib did not lead to any significant decrease in JAK3 270 phosphorylation ( Fig. 3C ). We also evaluated signaling through JAK3's primary pro-271 proliferative downstream mediator STAT5 (ref. 32). We found no evidence of STAT5 272 phosphorylation in either monoculture or co-culture ( Supplementary Fig. 2A ). These results 273 suggest that JAK3/STAT5 signaling is less central to stroma-supported MM growth. We further 274 confirmed this result using JAK3i, a newly-described, highly-specific, irreversible JAK3 275 inhibitor 32 . JAK3i had no effect on MM.1S in mono-or coculture (Fig. 4A ), nor did it show any 276 synergy with carfilzomib treatment (Supplementary Figure 2B-C) . 277
Taken together, these results suggest a mechanism whereby stromal cell-induced MM 278 proliferation is mediated through STAT3 transcriptional effects. These signaling pathways are 279 inhibited in an on-target fashion by tofacitinib, ultimately leading to reversal of the proliferation 280 phenotype. 281 282
Ruxolinitib has less anti-MM activity than tofacitinib 283
Given that our results above suggest a more important role for JAK1 and/or JAK2 in stromal-284 induced MM proliferation than JAK3, we turned to an alternate candidate for drug repurposing, 285 ruxolinitib. This agent, sold under the trade name Jakofi, is FDA-approved for use in 286 myeloproliferative neoplasms and has much higher affinity for JAK1 and JAK2 over JAK3 or 287 TYK2 (ref. 33). Treatment of U266 cells showed some anti-myeloma effect (Fig. 4B -C) but this 288 was significantly reduced compared to tofacitinib (Fig. 1) . Surprisingly, treatment of MM.1S 289 actually showed a promotion of growth at higher concentrations, both in the monoculture and co-290 culture settings ( Fig. 4B-C) . Western blotting demonstrated that 1 µM ruxolitinib was unable to 291 inhibit STAT3 activation in MM.1S in co-culture (Fig. 4D ). In fact, STAT3 phosphorylation 292 increased after 2 hr of treatment, consistent with the pro-proliferative effect seen in Fig. 4B -C. 293
To confirm that these effects could not be rescued with simultaneous inhibition of JAK1/2/3, as 294 accomplished by tofacitinib, we combined ruxolitinib with JAK3i. We found this combination 295 was also insufficient to recapitulate tofacitinib's effects in mono-or co-culture ( Fig. 4E-F) . 296
Taken together, these findings suggest that ruxolinitib is unable to inhibit pro-proliferative 297 STAT3 signaling in an in MM.1S cells, thereby supporting tofacitinib as having greater potential 298 as a repurposed anti-myeloma therapy. 299 300
Unbiased phosphoproteomics demonstrates that tofacitinib broadly reverses pro-growth 301 signaling induced by bone marrow stroma 302
Our targeted investigations above specifically focused on the JAK/STAT pathway. To further 303 elucidate the mechanism of tofacitinib in this system, as well as gain a broader view of stromal-304 induced proliferation and signaling in MM cells, we pursued unbiased mass spectrometry (MS)-305 based phosphoproteomics. We studied four samples, performed in biological replicate: 1) 306 MM.1S cells in monoculture; MM.1S cells in co-culture, either 2) untreated (DMSO control); 3) 307 treated with 1 µM tofacitinib for 1.5 hr; or 4) treated with 1 µM tofacinitib for 24 hr. We 308 harvested MM.1S cells in suspension, enriched for phosphorylated peptides using immobilized 309 metal chromatography, and analyzed by LC/MS-MS with peptide quantification performed using 310 MaxQuant 27 . 311
In total 4862 phosphopeptides had intensity data in all four samples and were used for 312 further analysis (listed in Supplementary Dataset 2). >99% of these sites are serine and threonine 313 phosphorylation events, consistent with other phosphoproteomic studies using this enrichment 314 method 34 . We first evaluated for phosphosites with >4-fold intensity increases in untreated co-315 culture vs. monoculture. Using our RNA-seq data as a proxy for protein-level changes, we 316 verified these phospho-site changes were largely driven by changes in signaling and not protein 317 abundance ( Supplementary Fig. 3 ). Panther pathway analysis revealed the only significantly 318 enriched pathway among the 544 upregulated phosphosites to be JAK/STAT signaling (Fig. 5A) . 319
However, based on Kinase Enrichment Analysis 35 , we found enriched signatures not only of 320 JAK1 substrates, but also other kinases driving proliferation and the cell cycle such as mTOR, 321 CDK1, and CDK2 (Fig. 5B ). These findings demonstrate that unbiased phosphoproteomics can 322 uncover broad signaling effects of the bone marrow microenvironment even downstream of 323 JAK/STAT. 324
Next, for validation of effects of tofacitinib treatment, we first examined Ser727 on 325 STAT3 (Fig. 5C ), a known JAK-responsive phosphosite 30 . Our quantitative MS results were 326 remarkably in line with Western blotting for another JAK-responsive phosphosite on STAT3, 327 Tyr707 (Fig. 3A) , with a very large increase in both phosphosites in untreated co-culture 328 compared to baseline, a >2-fold decrease in phosphorylation after short-term tofacitinib 329 treatment, and a rebound in phosphorylation at 24 hr. 330
This finding both serves to validate our phosphoproteomic data as well as help us define 331 a signature of tofacitinib-responsive phosphosites. Remarkably, 336 of the 544 up-regulated 332 phosphosites in untreated co-culture vs. monoculture (62%) met the same criteria of being 333 tofacitinib-responsive ( Fig. 5D-E) . Furthermore, examination across all measured phosphosites 334 demonstrates that while phosphorylation is broadly increased in the co-culture setting, noted as a 335 general shift toward positive phosphosite intensities in the untreated sample, treatment with 336 tofacitinib largely reverses this finding, re-creating a normal distribution around the intensity 337 values found in monoculture (Fig. 5F ). Taken together, these findings demonstrate that 338 tofacitinib broadly reverses the signaling pathways driving stromal-incuded proliferation in MM 339 cells, both at the level of direct JAK targets as well downstream proliferative signals, informing 340 our mechanistic understanding of this treatment beyond targeted Western blots alone. 341 342
Tofacitinib does not appear to have significant off-target activity 343
Another advantage of unbiased phosphoproteomics is potentially detecting additional off-344 target effects mediating tofacitinib response. We filtered for peptides that appeared unaffected 345 by stromal-induced signaling (less than +/-50% intensity change in untreated co-culture vs. 346 monoculture) that decreased in intensity >4-fold after 1.5 hr tofacitinib treatment (Fig. 6A ). We 347 identified only 54 peptides that fit this filter, and neither Panther nor Kinase Enrichment 348 Analysis identified any enriched signatures (not shown). Given the small number of peptides 349 and lack of any biological signatures, it appears most likely these 54 peptides are background 350 noise in the data and do not suggest any significant off-target effects of tofacitinib. 351
However, to further investigate the possibility of any off-target effects of tofacitinib, we 352 downloaded available data from the LINCS KINOMEscan database 353 (http://lincs.hms.harvard.edu/kinomescan/) and plotted versus the human kinase phylogenetic 354 tree (Fig. 6B) . These results demonstrate that, at least in cell-free assays, tofacinitib shows much 355 greater specificity for JAK-family kinases compared to ruxolitinib, which has numerous off-356 target activities. These findings underscore that tofacinitib's effects in this co-culture model 357 appear to be due to on-target activity. Furthermore, we speculate that through an as-yet-358 undefined mechanism, off-target effects of ruxolitinib may antagonize on-target JAK/STAT 359 inhibition in these MM models, leading to decreased efficacy of ruxolitinib compared to 360 tofacitinib. 361 362
Tofacitinib has anti-MM activity in the bone marrow microenvironment in vivo 363
Toward the goal of repurposing tofacitinib as an anti-MM therapy in patients, we next examined 364 the efficacy of tofacitinib in vivo. For this orthotopic disseminated xenograft model we used 365 luciferase-labeled MM.1S and U266 cell lines, which specifically home to the murine bone 366 marrow after intravenous implantation in NOD scid gamma (NSG) mice. Treatment was 367 initiated after two weeks of tumor growth and continued for four weeks at ~2/3 of the maximal 368 tolerated dose of tofacitinib (21.5 mg/kg/day by subcutaneous infusion) 36 . Encouragingly, we 369 found significantly increased murine survival in both of these cell line models ( Fig. 7A-B) as 370 well as decreased tumor burden based on bioluminescent imaging quantification ( Fig. 7C-D) . 371
These findings indicate that despite the in vitro rebound we observed in STAT3 activation (Fig.  372   3A) , continuous treatment with tofacitinib still leads to anti-myeloma effects in vivo. 373
We also performed in vitro studies of tofacitinib in combination with first-line myeloma 374 therapies carfilzomib and melphalan ( Supplementary Fig. 4 ). We found combination effects 375 with both of these agents in the co-culture model. Based on these results, in our U266 murine 376 study we also included study arms with carfilzomib alone at 2/3 of the maximal tolerated dose (2 377 mg/kg IV, 2x/week) and a combination of carfilzomib and tofacitinib at the above doses. We 378 found that tofacitinib led to similar lifespan extension as carfilzomib monotherapy, and also 379 found evidence of additive effects of the two agents, though the difference between the 380 combination and either monotherapy was not statistically significant. 381
We also tested tofacitinib versus two primary MM bone marrow samples treated ex vivo. 382
We did not see any significant viability effects of tofacitinib in either of these samples, against 383 either malignant plasma cells or other normal bone marrow mononuclear cells (Supplementary 384 Fig. 5 ). However, this result appears consistent with our in vitro and phosphoproteomic results, 385 which suggest that IL-6 dependent plasma cell proliferation is necessary for tofacitinib to have 386 any effect. Primary MM plasma cells isolated ex vivo in 2D culture are known to have minimal 387 ability to actively proliferate even in the presence of cytokines or stromal stimulation 37 . 388 Therefore, these results may more reveal the limitations of ex vivo patient assays in MM rather 389 than preclude the therapeutic efficacy of tofacitinib in MM patients, where plasma cells are 390 constantly proliferating in an IL-6-dependent manner within the bone marrow. 391
Discussion 393
Given the importance of the bone marrow microenvironment for MM pathogenesis, the 394 IL-6/JAK/STAT signaling axis has generated significant interest as a therapeutic target in MM. 395 JAK inhibition has already been validated in a number of preclinical studies as a way to target 396 this pathway 15-20 . However, the studied compounds are not yet available clinically and may 397 never be. Here, following the results of a large scale repurposing screen, we validated tofacitinib 398 as a potential therapy that can be rapidly translated into MM patients. 399
Using a combination of mechanistic pharmacology and unbiased mass spectrometry-400 based phosphoproteomics, we found that tofacitinib appears to inhibit stromal-induced 401 proliferation of MM plasma cells by inhibiting the IL-6/JAK/STAT signaling axis. Our results 402 support the use of unbiased phosphoproteomics both in kinase inhibitor evaluation and more 403 broadly in MM biology, where this method has been only applied in a very limited fashion. 404
Surprisingly, in our studies we found that the FDA-approved JAK1/2 inhibitor ruxolitinib 405 did not lead to the same anti-myeloma effects as tofacitinib, and in fact may paradoxically 406 promote plasma cell proliferation at high concentrations. We do note that ruxolitinib was 407 previously evaluated in a small trial of 13 MM patients in combination with dexamethasone 408 (NCT00639002) and no significant anti-MM effects were noted in this small study. Our in vitro 409 results here may provide a partial explanation for the lack of ruxolitinib activity in that trial. 410
We note that these studies are of course limited in that they are performed in MM cell 411 lines. While we primarily focused our analysis on the stromal-responsive cell lines MM.1S and 412 U266, which appear to better mimic the malignant plasma cell phenotype found in MM patients, 413 at this point focused clinical trials in MM will be necessary to truly evaluate whether tofacitinib 414 has anti-MM effects. 415
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